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Recommendations for Implementing 
Hepatitis C Virus Care in Homeless 
Shelters: The Stakeholder Perspective
J. Konadu Fokuo ,1 Carmen L. Masson,1 August Anderson,2 Jesse Powell,3 Dylan Bush,2 Margaret Ricco,3 Barry Zevin,4  
Claudia Ayala,2 and Mandana Khalili 2
Compared with the general population, homeless individuals are at higher risk of hepatitis C infection (HCV) and may 
face unique barriers in receipt of HCV care. This study sought the perspectives of key stakeholders toward establish-
ing a universal HCV screening, testing, and treatment protocol for individuals accessing homeless shelters. Four focus 
groups were conducted with homeless shelter staff, practice providers, and social service outreach workers (n  =  27) in 
San Francisco, California, and Minneapolis, Minnesota. Focus groups evaluated key societal, system, and individual-
level facilitators and barriers to HCV testing and management. Interviews were transcribed and analyzed thematically. 
The societal-level barriers identified were lack of insurance, high-out-of-pocket expenses, restriction of access to HCV 
treatment due to active drug and/or alcohol use, and excessive paperwork required for HCV treatment authorization 
from payers. System-level barriers included workforce constraints and limited health care infrastructure, HCV stigma, 
low knowledge of HCV treatment, and existing shelter policies. At the individual level, client barriers included com-
peting priorities, behavioral health concerns, and health attitudes. Facilitators at the system level for HCV care ser-
vice integration in the shelter setting included high acceptability and buy in, and linkage with social service providers. 
Conclusion: Despite societal, system, and individual-level barriers identified with respect to the scale-up of HCV ser-
vices in homeless shelters, there was broad support from key stakeholders for increasing capacity for the provision of 
HCV services in shelter settings. Recommendations for the scale-up of HCV services in homeless shelter settings are 
discussed. (Hepatology Communications 2020;4:646-656).
Hepatitis C virus (HCV) prevalence is under-estimated in underserved populations, including people experiencing homeless-
ness who are at increased risk of HCV infection.(1) 
According to a recent systematic review of infectious 
disease prevalence studies, the prevalence of HCV 
among homeless adults ranges from 9.8% to 52.5%.(2) 
Among people experiencing homelessness, substance 
use and mental health disorders are common, and are 
risk factors for HCV infection.(3,4) Moreover, home-
lessness has consistently been associated with injection 
drug use,(5) and engaging in unsafe injection drug-use 
practices likely drives the high rates of HCV infection 
documented among this population.(4,6-9) Despite the 
Abbreviations: DAAs, direct acting antivirals; HBF, Health Behavior Framework; HCV, hepatitis C virus; PWID, people who inject drugs; SUD, 
substance use disorder.
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high prevalence of HCV among homeless persons, a 
significant proportion still remains undiagnosed and 
consequently untreated.(10)
The perspective of health care providers and stake-
holders (i.e., shelter staff and directors, social service 
outreach workers and navigators) offer insight into 
the barriers and facilitators of HCV testing and treat-
ment experienced by individuals who are homeless or 
marginally housed, and are essential to the process 
of designing effective HCV service delivery mod-
els. In one study conducted before the direct acting 
antiviral therapy (DAA) era, patient-level barriers to 
HCV testing reported by shelter and health services 
staff among individuals experiencing homelessness 
included a lack of transportation, not having health 
insurance, unstable housing, medical mistrust, and 
a lack of mental illness and substance use disorder 
(SUD) treatment services.(11) These challenges high-
light the importance of rapid HCV point-of-care 
testing as one of the main health care needs of shelter 
clients.(11) However, despite the potential benefit of 
this testing approach and efficacy of DAAs, subopti-
mal uptake of HCV treatment persists among home-
less adults.(10,12,13)
From the perspective of primary care providers and 
hepatology specialists, previous research has iden-
tified patient, provider, and structural barriers and 
facilitators to HCV care.(14,15) Barriers to HCV care 
at the patient level included social stigma, homeless-
ness, substance use and mental health disorders, poor 
patient–provider communication, medication adher-
ence, lack of patient motivation, and fear of medica-
tion side effects.(14,15) Potential facilitators identified 
at the system level within these practice settings 
included the importance of the role of providers in 
educating and encouraging their patients to engage in 
and adhere to HCV treatment.(14,15) Moreover, formal 
patient education has been shown to enhance HCV 
knowledge and facilitate HCV management and 
coordination in both primary care and specialty clinics 
for underserved populations.(15,16) Therefore, a better 
understanding of the perspectives of health care pro-
viders and ancillary staff working in homeless shel-
ters is critical to guide the implementation of effective 
strategies to increase uptake of HCV screening and 
treatment among this at-risk population.
The primary goal of this study was to examine shel-
ter provider and ancillary staff perspectives on barriers 
and facilitators to increasing capacity for the provision 
of HCV services in the homeless shelter setting. We 
used the Health Behavior Framework(17,18) to conduct 
a comprehensive assessment of potential factors that 
could influence the integration of HCV services in 
homeless shelters, and used the information gathered 
to design a model of care to address HCV health dis-
parities experienced by homeless adults.
Methods
paRtiCipants
A total of 27 key stakeholders were recruited from 
four large homeless shelters located in San Francisco, 
California, and Minneapolis, Minnesota: two shelters 
in each respective city. A qualitative research design 
was used to gain a detailed understanding of pro-
vider opinions and attitudes toward the integration 
of HCV services in homeless shelters. Eligible par-
ticipants were shelter staff (i.e., staff and leadership), 
practice providers (i.e., registered nurses, nurse practi-
tioners, pharmacists, physicians, and physician assis-
tants), and social service outreach workers (i.e., patient 
navigators, case managers). Overall, four focus groups 
aRtiCle inFoRmation:
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were conducted: three in San Francisco and one in 
Minneapolis. In San Francisco, the first group (FG 
#1) consisted of practice providers (n = 5). The second 
group (FG #2) consisted of social service outreach 
workers (n = 6). The third group (FG #3) consisted of 
shelter staff (n = 4). The fourth group (FG #4), con-
ducted in Minneapolis, consisted of practice providers 
(n = 11) and a social service outreach worker (n = 1). 
The sample size selected (27 participants, four groups) 
was expected to provide adequate saturation of major 
themes.(19)
setting
The four homeless shelters from which participants 
were recruited served 300-400 marginally housed and 
homeless individuals per day and were located in 
urban areas. The shelters provided a variety of ser-
vices to their clients, including integrated urgent care, 
linkage to disability and other benefits, housing, and 
intensive case management. These shelters offered 
limited HCV testing and linkage to HCV services. 
These shelters shared a common mission to design 
effective HCV prevention and treatment models for 
people experiencing homelessness.
pRoCeDuRes
Shelter directors and medical directors working at 
each of the study sites identified eligible staff to par-
ticipate in the study. Invitations to participate in focus 
groups were sent to potential participants through 
e-mail correspondence. Each 60-minute focus group 
session was conducted between September and October 
2018 at the participating shelters using the same 
methods. Participants were not provided compensation 
for completing the interview. Each participant gave 
written, informed consent for the interview and audio 
recording. This study was approved by institutional 
review boards of the University of California, San 
Francisco, and Hennepin Healthcare in Minneapolis.
Focus groups were conducted by experienced facil-
itators using a semistructured interview guide (C.M., 
M.K., K.F., and J.P.). The interview guide consisted of 
open-ended questions that addressed key implemen-
tation issues, including shelter resources available to 
manage HCV, patient needs, attitudes toward the inte-
gration of HCV care in the shelter, potential barriers 
to integration of HCV services, previous knowledge or 
experiences in managing patients receiving treatment 
for HCV in the shelter, and recommendations for 
improving the delivery of HCV services (Supporting 
Information). Facilitators asked open-ended questions 
and used probes as needed to elicit more responses or 
expand ideas expressed by participants. Throughout 
the interview, facilitators used member checking by 
rephrasing key statements to verify accurate interpre-
tation of participant responses, which led to increased 
validity and credibility of the data.(20) A co-facilitator 
took detailed notes, operated recording equipment, and 
debriefed with the facilitator after the focus group ses-
sion.(21) Focus group discussions were digitally recorded 
and transcribed verbatim for thematic analysis.
The Health Behavior Framework (HBF) was used 
to guide the analysis and interpretation of the qualita-
tive interview data. The efficacy of the HBF as a guide 
for community-level intervention has been validated 
among multiple communities, including those at risk 
of HBV infection.(17) This framework is a multidimen-
sional model and synthesizes multiple models of health 
behavior, social theory, and change to map factors that 
influence behavioral intentions, thereby influencing 
health behavior.(18) By dividing influencing factors 
into societal, system, and individual levels, this model 
allows for the consideration of barriers and facilitators 
in terms of the level of their projected impact.
QualitatiVe Data CoDing anD 
Data analyses
We used deductive theory-driven thematic analy-
sis to find underlying meaning in the text, which is 
the iterative process of coding, review, discussion, and 
revision.(22) A thematic analysis is not dependent on 
a quantifiable measure, but rather the data are coded 
to capture predominant or important themes in rela-
tion to a specific research question or issue.(22) In the 
first stage of the analysis, three coders (C.M., K.F., 
and A.A.) read responses line-by-line to obtain an 
understanding of the text and overall impression of 
the material. Second, important meaning units (i.e., 
line, sentence, or paragraph) were identified. Third, 
the meaning units were identified and labeled with 
codes, then grouped into categories and subcategories. 
Coders met on four separate occasions to compare 
coding choices, suggesting possible codes and defini-
tions for the codebook. Once consensus was reached 
about the acceptability of code labels and definitions, 
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coders used the refined cookbook and independently 
assigned codes to the transcripts. This iterative pro-
cess of coding continued until all of the text in the 
transcripts had been coded.
Using the HBF, themes were further sorted into 
societal, system, and individual levels, allowing us to 
consider their projected impact. Societal-level factors 
are community-based characteristics specific to the 
homeless population, which may affect the implemen-
tation of rapid HCV point-of-care testing and treat-
ment in urban-based homeless shelters. System-level 
factors are characteristics specific to health delivery 
infrastructure (i.e., provider, health care system, shel-
ter system) within the context of homeless shelters. 
Individual-level factors are features perceived by the 
participants to reflect characteristics specific to peo-
ple experiencing homelessness using shelters that may 
affect the implementation of an HCV testing and 
treatment protocol. Illustrative quotations were cho-
sen from the interviews. To ensure confidentiality, all 
quotes from participants have been de-identified.
Results
Based on the HBF, we identified barriers and 
facilitators at the societal, system, and individual 
level. Several major themes emerged from our anal-
ysis, which informs our recommendations and next 
steps for the successful implementation of a universal 
HCV screening, testing, and treatment program. At 
the societal level, health insurance was the predomi-
nant theme. System-level themes included workforce 
constraints, changing the HCV treatment narrative, 
low HCV treatment knowledge, shelter policies, high 
acceptability and buy-in from staff, and linkage with 
social service outreach workers. Individual-level themes 
included competing priorities, behavioral health needs, 
health attitudes, and prescriber’s attitudes about people 
who inject drugs (PWID). Below, we describe exam-
ples related to the major themes identified within 
societal, system, and individual-level factors.
soCietal-leVel BaRRieRs
insurance
The most important barrier identified by FG 
#1 and FG #4 to receipt of HCV care is related to 
health insurance access and policies. They specifi-
cally noted a lack of insurance coverage, high out-
of-pocket expenses, restrictions on treatment due to 
drug and/or alcohol use, and excessive paperwork 
required to obtain treatment authorization from 
payers.
There is a lot of caveats from insurance companies 
which require authorizations around clean urine drug 
screens and looking at the ability of the client to be able 
to adhere to treatment plans. (FG #4)
I did a lot of communications with them (insurance 
companies) and the pharmacies about medications for 
hepatitis C and I think that was a big thing that took 
up a lot of our time. And clients didn’t want to sit for 
these interviews and questions. (FG #1)
soCietal-leVel FaCilitatoR
There were no particular societal-level facilitators 
reported by the participants.
system-leVel BaRRieRs
Workforce Constraints in the shelter
Workforce constraints and a limited health care 
infrastructure to treat HCV were cited as import-
ant barriers to expanding HCV services in shel-
ters. Practice providers reported inadequate time for 
screening, testing, and treating clients with a complex 
clinical presentation.
Folks have to understand that the shelters have the 
sickest, most complicated people under one roof with 
one nurse and three hundred and f ifty people. (FG #1)
Shelters are not equipped with laboratories; 
specimens would need to be couriered out in these 
settings. Shelters also do not have pharmacies; 
therefore, medications for HCV treatment would 
have to be delivered from pharmacies to clients, and 
appropriate systems set up to store and dispense 
medications.
[Time consuming] Setting up deliveries. In the past 
those medications would get delivered to the wrong site 
and I would have to track that down. (FG #1)
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[It takes 3-5 days to get lab results]. It’s a barrier. And 
[…] We have a positive lab mechanism where we keep 
trying to do follow ups to capture the patient, but it can 
still take a couple of weeks. (FG #4)
HCV treatment narrative
Many social service outreach workers, practice 
providers, and shelter staff reported a need to change 
the HCV treatment narrative. Participants were 
familiar with the difficulties of HCV treatment in 
the interferon-based era and the narrative related to 
HCV treatment at that time.
There needs to be some education around […] new 
treatments available now. It’s not like the interferon 
back in the day where you’d have to go through six, nine 
months of treatment and it was not very pleasant and it 
wasn’t a hundred percent cure anyway [The new treat-
ment] is much more time eff icient. (FG #3)
Educating them (patients) about the current treatment 
regimens, that they are shorter, […], kind of under-
standing if people have had negative experiences with 
friends or family being treated in the past when regi-
mens were much more challenging. (FG #4)
Other participants further commented that they 
believed that the interferon-based HCV treatment 
narrative may have contributed to delays in providers 
deciding to refer clients for treatment.
I feel like […] the narrative that is out there on the 
street is the battle days of interferon, everyone was 
told to just wait with their Hep C. They found out 
they were living with Hep C, and they (doctors) said, 
‘well you know it’s never an emergency and just wait 
on it.’ (FG #2)
Now we have better treatments, so we have to tell pa-
tients, why wait? Cure Hep C now. (FG #2)
low HCV treatment Knowledge
Participants were generally aware of HCV and its 
risk factors, and knowledgeable about strategies to 
prevent HCV infection. However, shelter staff indi-
cated low knowledge about HCV care and specified a 
need for training to improve their knowledge of HCV 
treatment.
I don’t know that much about (HCV) treatment. We 
have not had anyone at our (center) go through the full 
course of treatment. (FG #3)
Practice providers were knowledgeable about HCV 
and its treatment, but there were site differences with 
respect to their experiences in treating HCV in shelters. 
In Minneapolis, there was limited experience in treat-
ing HCV in the homeless shelter setting, while in San 
Francisco, participants acknowledged they had some 
had experience in treating HCV among shelter clients.
We don’t have much experience. We don’t currently treat 
in the shelters. (FG #4)
A few people have been treated in the shelter. We have done 
a couple, one in particular that I know we helped (refer to 
specialty treatment) and it was successful. (FG #1)
shelter policies
Participants in San Francisco indicated that shelters’ 
specific policies regarding admittance and continuity 
of residence within the shelters may limit a client’s 
stay. Thus, continuity of shelter residence cannot be 
guaranteed for the duration of treatment. In addition, 
they reflected that shelter policies regarding behavioral 
health disorders (substance use and mental illness) can 
cause frequent termination of clients’ stays at the shelter.
There are restrictions on how [appearance] you can 
show up at a shelter. You are talking about active drug 
users bringing in their syringes and [shelter policy] says 
you can’t bring your syringes here. (FG #2)
You may initiate somebody in a shelter and then they get 
bounced for drug use or for having an episode [where] 
they are agitated or acting violently. […] You get kicked 
out for that. (FG #2)
system-leVel FaCilitatoRs
High acceptability and Buy-in
Participants in both locations expressed high 
acceptability and buy-in from city and county officials 
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for increasing capacity to provide HCV testing, treat-
ment, and linkage services to homeless clients.
Integrating HCV treatment in the shelter will go a long 
way for people to access care. (FG #4)
Treating (patients) with Hepatitis C, it’s wonderful, 
it’s fantastic that we are able to treat it and actually 
cure it. (FG #1)
Furthermore, participants in both locations viewed 
the leadership and culture of organizations as major 
facilitators of the implementation of onsite HCV 
management to optimize HCV care for their clients. 
Participants stated that in San Francisco, many orga-
nizations received onsite education as part of a city-
wide initiative to eradicate HCV. These education 
programs positively informed providers’ and staff ’s 
knowledge, attitudes, and beliefs.
“They [the City and County of San Francisco] really care 
about ending Hepatitis C; they’ve put a lot of money and 
resources towards it. It’s very important in this [home-
less] population because they are high risk.” (FG #1)
linkage With social service providers 
and outreach Workers
Participants stated that engaging existing social 
service providers and outreach workers catering to 
homeless individuals helped broker trust between 
clients and health care providers. These social ser-
vice agencies assisted clients in establishing health 
insurance, providing case management, offering 
harm-reduction programs to patients with SUDs, and 
providing referrals. Participants especially praised the 
collaboration with local social services agencies that 
assisted in screening clients at the homeless shelters 
and helping to track patients in the community.
Now with [social service outreach in the community] 
helping, it’s great. They are doing the testing once a 
week at each homeless shelter. They call me when they 
have a positive screen and I’ll refer them for treatment. 
It’s a much easier process. (FG #1)
The collaboration and the relationship building that we 
do across agencies is really important because no matter 
where this person sort of gets pushed, or falls into, they 
will arrive somewhere else and then we will be able to 
link them again. (FG #2)
Having a community health worker to be really dedi-
cated to outreach is great. […] they can help with track-
ing patients and medication adherence. (FG #4)
inDiViDual-leVel BaRRieRs
Competing priorities
At the client level, unstable housing, competing 
priorities, and inaccurate perceptions about HCV 
infection and treatment were identified as barriers. 
Participants defined competing priorities as acts of 
daily living that require greater effort due to housing 
status, such as needing to secure food, engaging in 
personal hygiene, meeting employment responsibili-
ties when present, and lack of transportation.
Because most of our clients have multiple comorbidities and 
this (Hepatitis C) might not be their priority. (FG #4)
It’s a very chaotic world (for patients) and there’s compet-
ing priorities. I gotta eat; I got to find some shoes. (FG #1)
Behavioral Health
Behavioral health conditions were perceived to 
cause difficulty with maintaining residence in the 
shelter, remembering appointments, and adhering to 
treatment. Many practice providers reported that hav-
ing a SUD negatively affects treatment due to insur-
ance provider restrictions on who, among individuals 
with chronic HCV, may receive treatment.
I think substance abuse impacts our clients’ abilities to 
actually engage in care. (FG# 4)
(Medication) adherence is diff icult in the population 
because of theft, intoxication, losing their stuff; yeah they 
you know, alcohol, drug abuse. (FG #1)
Furthermore, social service outreach workers re-
ported that people who have substance use disorders 
may be deterred from therapy due to perceived social 
stigma from providers who may have negatively bi-
ased views of people with substance use issues, and 
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thus many PWID may not believe providers will treat 
their HCV.
We have people (saying) like oh ‘it’s ninety thousand 
dollars for treatment, aw I’ll never get that because I’m 
just this humble homeless person.’ They’ll just kind of 
(have) Stockholm syndrome that they (think they) are 
worthless people. (FG #2)
peRCeiVeD FaCilitatoR
Health attitudes
Some participants noted that people experiencing 
homelessness care about their health and that they are 
willing to engage in medical care if given the opportunity.
It’s a misconception to think the homeless don’t care 
about their health; they do. They just need help to man-
age it. (FG #1)
On the down low (homeless) people are concerned about 
their health, I mean straight up. (FG #2)
prescriber’s attitudes about HCV 
treatment among active injection 
Drug users
Participants in Minneapolis indicated that, in the 
past, some treating providers were reluctant to initiate 
HCV treatment in the context of active injection drug 
use due to concerns about treatment nonadherence or 
reinfection. Currently, providers no longer delay treat-
ment among active injection drug users.
Regardless, I still refer people (for HCV treatment) if 
they are actively using. (FG #4)
I think the majority of us (shelter practice providers) 
embraces risk reduction, and we would be […] less con-
cerned about if they (the patient) were using, but more 
concerned with [their] consistency with follow up and 
their ability to engage with us and their compliance 
with their medication. (FG #4)
In contrast, focus group participants in San 
Francisco did not discuss prescriber’s attitudes about 
HCV treatment among active injection drug users.
ReCommenDations FoR 
suCCessFul implementation 
oF sHelteR-BaseD HCV 
testing anD tReatment
Participants provided the following recommenda-
tions to successfully implement HCV care within the 
shelter setting:
1. Offer the shortest possible course of HCV therapy: 
Practice providers in both locations suggested 
a shorter course of HCV therapy for this 
population.
Because in this population, they are getting moved 
around a lot, right? And so a shelter bed might be for a 
short period of time. It’s better to have a shorter course. 
(FG #4)
Two months (treatment) are a lot easier. […] for people 
it’s a big difference. (FG #1)
2. Establish a designated HCV coordinator: To address 
workforce constraints and provide comprehensive 
HCV care (i.e., screening, testing, education, med-
ications, and client follow-up).
You have a designated nurse with that phone, and some-
one can just communicate directly, […] and then just do 
a warm hand off. Then (the designated nurse) coordi-
nates the blood draws, run to the lab, dispense medica-
tions and do teaching. (FG #1)
More care coordination staff. You know like having the 
dedicated hepatitis C nurse that […] is huge. (FG #4)
3. Use incentives to engage patients in follow-up care: 
Several participants attested to the possibility of 
better medical engagement once the traditional 
model of health care is adjusted to the context 
of homelessness. Participants described innova-
tions such as using case-management services 
during therapy, incentivizing treatment (e.g., food, 
money), increasing access to behavioral health ser-
vices, scheduling evening clinic hours, and using 
community peer navigators to locate and motivate 
patients to engage in treatment.
I think our patients are very motivated by incentives, […] 
Some Gatorade, some food, snacks, gift cards. (FG # 4)
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If you are using gift cards, put the biggest amount at 
follow-ups. (FG #1)
4. Provide extended shelter stay for those in treatment: 
Participants in San Francisco suggested extending 
shelter stay opportunities for patients in HCV care.
That could also be another incentive if something was 
worked out as far as like we have reserved x amount of 
beds for people actively engaging in some sort of (HCV) 
treatment. (FG #3)
5. Provide education for staff: Shelter staff ’s limited 
knowledge of HCV and its treatment highlights 
the importance of providing HCV education for 
staff working with vulnerable populations at high 
risk for HCV. Providing HCV education may 
increase staff ’s self-efficacy to support the HCV 
treatment needs of their clients.(23)
“I’m glad you mentioned the staff education component. 
I had some questions about that (treatment) and some 
really basic questions, like what’s Hep C, is that air-
borne?” (FG #3)
6. Offer peer navigation or support groups led by peer fa-
cilitators (i.e., people with shared life experience): Focus 
group participants noted that peer-based education 
could enhance trust, social support, increase HCV 
knowledge, and reduce perceived stigma.
(Trained peers) go out into the community and they 
(homeless clients) feel like you’ve got somebody who looks 
like you, who has the same infection as you, but has cured 
it, it’s a very compelling testimony. (FG#2)
7. Provide formal HCV education for clients: As we have 
demonstrated in our previous work, HCV formal 
education substantially improves patient knowl-
edge of HCV disease in a vulnerable and diverse 
patient population.(24) A patient-centered approach 
to health care in HCV-infected vulnerable popula-
tions, such as people experiencing homelessness, 
has the potential to address unmet HCV health 
care needs and improve patient outcomes.(16)
You (a provider) just kind of engage them on that level 
while it’s going on so they are getting a little bit of edu-
cation during that time. (FG# 3)
Discussion
This study explored perspectives of shelter staff, 
health care practice providers, and social service out-
reach workers as stakeholders on ways to implement 
HCV screening, testing, and treatment in urban 
homeless shelters. Although previous research has 
assessed provider stakeholder perspectives within spe-
cialty and primary settings, we expanded the litera-
ture by focusing on facilitators and barriers for HCV 
care within shelters in two distinct urban locations 
(Minneapolis and San Francisco). We found that 
despite societal, system, and individual-level barriers 
identified as related to the scale-up of HCV services, 
there was broad support from stakeholders for the 
integration of HCV services within the shelter setting. 
We also identified key recommendations to ensure the 
successful scale-up of HCV services within homeless 
shelters.
Our findings suggest several societal, system, and 
individual-level barriers and facilitators that spanned 
the HCV care continuum from case identification 
or diagnosis to treatment management. Our results 
demonstrate shelter management in San Francisco 
and Minneapolis has high acceptability and buy-in 
for expanding HCV care. Although some of the iden-
tified barriers are difficult to modify, others may be 
more amenable to change, such as enhanced educa-
tion for staff, a dedicated support system with trained 
personnel, peer-based education, and navigators and 
social support(25,26) to enhance HCV knowledge. 
These were suggested as possible solutions to facilitate 
successful implementation. Our results further suggest 
that provision of linkage or integration of behavioral 
health services may enhance HCV treatment adher-
ence, particularly among PWID. The process of inte-
gration ranges from services co-located in a single 
clinic(27,28) to facilitated behavioral health referrals at 
HCV treatment clinics, and may even include a mix 
of these; these service delivery models could also be 
considered for implementation in shelter settings. 
Similar approaches have been met with success in the 
treatment of HIV in PWID by integrating mental 
health or SUD treatment services within the context 
of anti-retroviral treatment delivery.(29)
Integrating services for HCV in shelter settings 
could mitigate several logistical barriers that PWID 
experiencing homelessness commonly encounter, 
such as other competing priorities that may cause a 
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patient to miss an appointment. A recent systematic 
review of integrated models of care for people who 
inject drugs and have chronic hepatitis C infection 
suggests that a one-stop shop model of care that inte-
grates HCV care in addiction-treatment programs or 
community settings may facilitate engagement along 
the continuum of HCV care for this population.(30) 
Additionally, community-based HCV treatment by 
primary care providers may offer a promising strat-
egy to reach people experiencing homelessness.(12) 
However, in shelters where multidisciplinary resources 
are lacking, health care providers, shelter staff, and 
social service outreach workers must advocate for 
patients in ways that can move the patient toward 
treatment. Advocacy may include securing housing, 
social work interventions, intervening on behalf of the 
patient with insurance companies, which can result 
in an increased workload for providers and may lead 
to clinician burnout.(31) We also identified a need to 
increase awareness and understanding of the benefits 
of treatment with DAAs among patients, providers, 
and key stakeholders.(32) Some stakeholders perceived 
patients to be wary of treatment because of known 
historical side effects. Stakeholders suggested enlisting 
the help of peer educators(33) who can act as a bridge 
between the patient and provider, to increase motiva-
tion for treatment and to reduce self-stigma among 
patients with HCV and provide encouragement to 
engage and comply with treatment.
Based on previous research on integrated models 
of care for at-risk populations with HCV(30) and our 
formative work reported herein, we are currently eval-
uating scaling up HCV testing and a flexible model 
of integrated HCV care and treatment. In this model, 
a designated provider (a nurse in San Francisco and 
a pharmacist or physician assistant in Minneapolis) 
performs incentivized HCV point-of-care testing and 
confirmation of active infection, formal patient group 
education, assessment of treatment readiness, and 
links the patient to HCV therapy.(34) HCV therapy 
is offered by shelter practice providers or a designated 
onsite HCV nurse coordinator, as well as through 
referral to offsite primary care providers or hepatol-
ogy specialists. This ongoing study seeks to evaluate 
whether this one-stop shop model of care can be 
applied in homeless shelter settings to reach HCV-
infected persons who are homeless and improve their 
engagement along the continuum of HCV care.
Limitations of the study should be noted. This 
study focused on four shelters with 24-hour access 
and options for extended stay, such as receiving 
care for serious medical conditions or transition-
ing to permanent housing. These shelters also had 
pre-existing clinics with linkage to case manage-
ment embedded in their infrastructure. Clients at 
these shelters therefore had more stable housing 
than clients in other traditional or homeless respite 
centers (i.e., navigation centers). Inclusion of nav-
igation centers and more transitional populations 
may have increased generalizability of these results. 
Participants’ demographic information such as age, 
race/ethnicity, gender, and length of employment 
or practice were not collected, as the staff at the 
programs viewed this information as too sensitive 
to share in the context of a focus group in a work 
environment. Therefore, we cannot report and com-
pare the narratives according to these demographic 
characteristics. Additionally, participants knew and 
worked with each other, and one focus group con-
sisted of providers who held different roles at the 
shelter; thus there is the possibility that some par-
ticipants did not want to disagree with their super-
visors, and did not express their own opinions. It 
is also possible that participants may have provided 
socially desirable responses, because it was known 
that the interviewers were developing a service deliv-
ery model to support access to HCV care. Finally, it 
would be beneficial in future research to study bar-
riers and facilitators to HCV care among practice 
providers working in shelters in other regions of the 
country, and to identify similarities and differences 
by region.
This study identified several areas for targeted 
intervention at the societal, system, and individual 
level, to facilitate the successful integration of HCV 
screening, rapid point-of-care testing, and treatment 
in homeless shelters. Integrating psychosocial ser-
vices to enhance linkage to SUD treatment and/or 
mental health services is critical in providing com-
prehensive HCV care for people experiencing home-
lessness. Addressing issues such as workload and time 
pressures for practice providers with trained HCV-
designated personnel could reduce system barriers 
and improve treatment continuity with this popula-
tion. Finally, while new therapies for HCV have high 
efficacy when taken correctly, there was a perception 
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that patients’ narrative of HCV treatment remains 
entrenched in past therapies, and providers may not 
be knowledgeable about advancements in HCV treat-
ment. To address this knowledge gap, educational pro-
grams for providers as well as formal HCV patient 
education programs and peer education within shel-
ters should be key intervention components of com-
prehensive HCV care to increase HCV testing and 
cure rates within the homeless population. As the 
landscape for HCV treatment continues to evolve, 
future studies may identify new barriers or potential 
solutions to address gaps in HCV treatment among 
people experiencing homelessness.
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